Top Biotech Companies in Singapore (110)
CECO Environmental is a global leader in air quality and fluid handling serving the energy, industrial and other niche markets. Providing innovative technology and application expertise, CECO helps companies grow their business with safe, clean and more efficient solutions that help protect our shared environment. In regions around the world, CECO works to improve air quality, optimize the energy value...
For over 240 years, Takeda’s propensity to evolve has driven the next generation of innovation, and as a future-focused organization, we’re continuing to drive forward with endurance in our steadfast pursuit to achieve the best outcomes for our patients in a rapidly changing world. We have been preparing for this period of value creation by investing in data, digital and...
Takeda's Top Stability & Growth Strengths
Strong Market Position & Advantage: Takeda is consistently placed among the global top 15–20 by revenue and is a clear category leader in GI/IBD, plasma-derived therapies, and dengue vaccines with broad international authorizations and WHO support. Subcutaneous ENTYVIO and new oncology approvals like FRUZAQLA broaden real‑world use and extend reach.
Profitability: Reported FY2025 operating profit rose 19.3% year over year and EPS nearly doubled despite a slight revenue decline, supported by lower amortization and restructuring expense. Core profitability remained broadly stable as Growth & Launch Products expanded their share.
Future-Ready Strategy: Management is investing through FY2026 to convert a late‑stage pipeline (e.g., oveporexton, rusfertide, zasocitinib) into multiple launches, with Growth & Launch Products prioritized as near‑term engines. A multi‑year transformation and efficiency program targeting significant savings by FY2028 is intended to fund launches and strengthen competitiveness.
Biomatch specializes in connecting top talent with leading companies in the life sciences sector, including pharmaceuticals, biotechnology, and medical technology. They offer tailored recruitment solutions, conduct candidate assessments, and aim to find the right job match for candidates and experts for companies.
For 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies,...
Merck's Top Stability & Growth Strengths
Strong Market Position & Advantage: Merck holds a clear leadership position, anchored by Keytruda—the world’s top‑selling cancer medicine at $31.7B in 2025—and strong standings in vaccines and overall scale among global pharmas. Animal health also ranks among top players, reinforcing breadth across key healthcare markets.
Innovation-Driven Growth: A broad late‑stage pipeline and scientific presence (100+ ASCO 2026 abstracts across 25+ tumor types) span oncology, vaccines, infectious disease, and cardiometabolic areas. Ongoing label expansions and new formats like subcutaneous Keytruda (including U.S. Keytruda Qlex) are adding growth vectors.
Diversified Revenue Streams: Sales draw from oncology, vaccines (e.g., Gardasil over $10.7B in 2025), hospital acute care, and a growing animal health segment. Newer launches and alliances (e.g., Winrevair, IDVYNSO, and partnered oncology assets) are contributing to mix.
AUM Biosciences is focused on advancing a clinical pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance
Respiree© is a digital therapeutics company providing personalized healthcare services for chronic cardio-pulmonary disease management using a combination of proprietary breath-cardio sensors, AI and workflow integrated UIUX. The iRIS platform by Respiree© uses data captured from remote-patient-monitors, mobile applications and medical records to longitudinally measure, track disease progression and create reports for physicians and hospitals.
About the Agency for Science, Technology and Research (A*STAR) The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector agency that spearheads economic oriented research to advance scientific discovery and develop innovative technology. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit society. As a Science and Technology Organisation, A*STAR...
A*STAR - Agency for Science, Technology and Research's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Multi‑year national R&D allocations and top‑ups (RIE2025, RIE2030 S$37B, S$1B AI plan) and new earmarks (S$800M semiconductor flagship, S$500M biomedical refresh, NSTIC budgets) provide substantial funding capacity. These commitments underpin expansions in semiconductors, biomedicine, AI, and decarbonisation.
Strategic Partnerships: Deepening joint labs and collaborations with global and local industry (e.g., Rolls‑Royce–SAESL, Applied Materials at ARTC, Flagship Pioneering up to SGD100M, Labcorp facility) signal strong co‑development pipelines. Fresh bilateral calls and ecosystem partners committing capital reinforce translation momentum.
Future-Ready Strategy: Mission‑oriented expansions into semiconductors, AI, nucleic‑acid therapeutics, and sustainability, coupled with platforms like NSTIC and the mRNA BioFoundry, position the agency for emerging national priorities. Relocation and clustering of institutes (e.g., Jurong Innovation District; Biopolis refresh) support faster lab‑to‑market translation.
Livestock disease prevention and sustainable agri productivity. Singaporean synbio startup funded by EF Venture Capital.
Kemin Industries is a global ingredient manufacturer that strives to sustainably transform the quality of life every day for 80 percent of the world with its products and services. The company supplies over 500 specialty ingredients for human health, food safety and protection of the global food supply chain. Kemin ingredients offer solutions across various industries including animal health, nutraceuticals,...
Since Bio-Rad was founded 70 years ago, we have continued to provide the healthcare industry with innovative and useful products that help life science researchers accelerate the discovery process and medical diagnostic labs obtain faster, better results. Throughout our existence, we have built long-lasting customer relationships that help advance our research and development efforts in the introduction of new products...
TW Metals is a global specialty-metals distributor that stocks and processes tubing, pipe, bar, rod, wire, plate, coil, sheet, aerospace extrusions and related products. Its materials include stainless steel, aluminum, nickel, titanium and carbon alloys. The company operates an international distribution network, offers processing services such as cutting, and supplies specialty metal products to aerospace and commercial customers worldwide, supporting...
Founded in 2019, Virtue Diagnostics is an in vitro diagnostic provider committed to platform innovation in emerging markets. We have built a management team with decades of experience in the in vitro diagnostic industry and a global vision, coupled with robust R&D, operation and commercialization capabilities. We set up our industrialization bases in China, Brazil and Indonesia, and R&D centers...
At KROSSLINKER, we innovate and transform Aerogel for challenging insulation applications. Our first product aims to serve the cold-chain biopharma packaging industry by protecting temperature-sensitive pharmaceuticals, precious biologics, and vaccines throughout their shipping journey with our transformative technology.
At Elekta, our outcome-driven and cost-efficient solutions provide lasting clinical difference and are developed through sustainable environmental, social and governance practices. We’ve been working openly and proactively with clinicians and our partners for almost half a century to advance precision radiation therapy and meet continuously evolving patient needs—no matter where they are in the world. To us, it's personal, and...
Elekta's Top Stability & Growth Strengths
Strong Market Position & Advantage: Elekta is a top-tier radiotherapy vendor with category leadership in cranial stereotactic radiosurgery and a notable presence in high-field MR-guided therapy, reinforcing durable competitive standing. Recognition for oncology information systems further supports its positioning in cancer centers.
Innovation-Driven Growth: Recent launches such as Elekta Evo and the Elekta ONE software suite, alongside continued advancement of Unity MR‑Linac workflows, indicate a pipeline that is aiding orders and improving mix. These innovations underpin adaptive and image‑guided therapy strategies across the portfolio.
Resilient & Sustainable Growth: Book‑to‑bill ratios above 1.0 and low single‑digit constant‑currency sales growth point to steady underlying expansion. Improving adjusted margins in recent quarters suggest operational gains despite macro headwinds.
Rakuten Medical, Inc. is a global clinical stage biotechnology company developing and commercializing precision, cell-targeting investigational therapies on its AlluminoxTM platform, which, in pre-clinical studies have been shown to induce rapid and selective cell killing and tumor necrosis. Outside of Japan, Alluminox therapies have not yet been approved as safe or effective by any regulatory authority. The company’s first drug...
Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.
Illumina's Top Stability & Growth Strengths
Strong Market Position & Advantage: Feedback suggests Illumina maintains dominant leadership in short-read NGS with a broad installed base, end-to-end workflows, and wide adoption across research and clinical markets. This entrenched position supports recurring consumables pull-through and reinforces competitive advantage.
Profitability: Feedback suggests profitability and margins improved with a stronger year-end quarter, rising EPS, and robust free cash generation supporting restructuring and reinvestment. Operating performance strengthened year over year, indicating better cost discipline and a healthier earnings profile.
Innovation-Driven Growth: Feedback suggests product and technology innovation—including NovaSeq X adoption and advances in AI/informatics—is driving utilization and clinical momentum. Partnerships and acquisitions broaden multiomics capabilities and underpin a roadmap focused on further cost and throughput gains.
Catalent Inc. (NYSE: CTLT), an S&P 500® company, is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health...
In a rapidly changing industry, caregivers remain the constant. Every day they demonstrate their passion for helping people despite unprecedented pressure to increase access and quality of care with the same or fewer resources. Hillrom is driven by patient-centered care. Everything we do, and all our products and technologies, are designed to enhance outcomes for patients and caregivers. It starts...
Kele, Inc. is a premier stocking distributor of building automation systems (BAS) and HVAC parts. The company provides a comprehensive range of sensors, transmitters, and control devices, alongside custom panel shop and specialized project engineering services, aiming to simplify the supply chain and enhance operational efficiency for commercial and industrial facilities.
Esco Lifesciences is a world-leading manufacturer and service provider of life science tools. Esco contributes to meeting the challenges of the 21st century with a diverse range of business units—Scientific, Medical, Healthcare, and Aster. The company continuously innovates its products to help clinical and industrial laboratories conduct successful research and development, quality control, and analysis. Esco continues to provide reliable...
ESCO's Top Stability & Growth Strengths
Market Expansion: Public signals indicate the company opened a China headquarters in 2025, brought South Korea sales/service in‑house in 2024, and expanded EU manufacturing with a new Lithuania plant, alongside partnerships that broaden reach. Evidence also highlights sales in 100+ countries and operations spanning 24 countries, pointing to a broad and active commercial footprint.
Investor Backing & Capital Strength: A record-setting, oversubscribed US$200M Series A in 2021 led by Novo Holdings and Vivo Capital signals strong institutional confidence and funding for expansion, M&A, and R&D. Subsequent acquisitions, facility openings, and partnerships align with the stated use of proceeds and reinforce capital-enabled growth.
Strong Market Position & Advantage: Multiple independent market summaries consistently list the company among top global competitors in biosafety cabinets and clean‑air workstations, indicating leadership within that segment. A large installed base and global operations presence reinforce recognition across labs, hospitals, and biopharma.
